When it comes to coping with chronic angin a—chest pain or pressure that comes on when the heart isn't getting enough oxygen, usually during physical activity—a positive outlook may help improve outcomes over time, according ...
Mar 1, 2018
0
1
Coronary artery stents are lifesaving for heart attack patients, but new research suggests that the placebo effect may be larger than previously thought.
Nov 2, 2017
0
3
An analysis of data from the entire development program consisting of three trials assessing the feasibility of using a stem cell therapy (CD34+ cells) to treat patients with the most severe cases of angina, refractory angina ...
May 11, 2017
0
3
The absolute cumulative probability of death at 12 months was 5 percent lower for patients who received routine invasive coronary angiography and revascularization as indicated during an unstable angina admission compared ...
May 1, 2017
0
0
Patients with acute coronary syndrome who were treated with the blood-thinning drug rivaroxaban in addition to an antiplatelet medication (clopidogrel or ticagrelor) experienced no increase in bleeding complications compared ...
Mar 20, 2017
0
0
Lipoprotein apheresis, a therapy normally used to filter excess cholesterol from the blood of patients with familial hypercholesterolemia, may have a new role in patients with refractory angina.
Aug 29, 2016
0
0
A two-year, multi-center clinical study with 167 patients with class III-IV refractory angina randomized to low and high dose CD34+ cells or placebo has revealed that patients who received either a high or low dose of CD34—a ...
Jun 1, 2016
0
1
Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol ...
Apr 4, 2016
0
1
(HealthDay)—For patients with angina pectoris, ivabradine is associated with improvements in certain parameters of quality of life (QoL), according to a study published online Dec. 22 in Circulation: Cardiovascular Quality ...
Dec 23, 2015
0
0
(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...
Dec 3, 2015
0
0
